Greetings, and welcome to the KZR-616 Data from ACR Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Celia Economides. Please go ahead.
Thank you, Kevin. Good morning, everyone, and welcome to Kezar's conference call to discuss KZR-616 and the new data we're reporting for the MISSION Phase 1b trial during the American College of Rheumatology 2019 Annual Meeting. With me on the call today from Kezar are John Fowler, our Chief Executive Officer; and Christopher Kirk, President and Chief Scientific Officer.
This morning, we issued a press release detailing the results presented with KZR-616 from the MISSION Phase 1b study in SLE patients. The press release is available on our website. The slides used for today's call are on the webcast on the Investor section of our website.
During the course of this call, we will make forward-looking statements based on current expectations, so these forward-looking statements are subject to a number of significant risks and uncertainties and our actual results may differ materially from those described. We encourage you to review the Risk Factors in our most recent Form 10-Q filed with the US Securities and Exchange Commission and available on our website. All statements on this call are made as of today based on information currently available to us. Except as required by law, we disclaim any obligation to update such statements even if our views change.
With that let me turn the call over to John. John?
Thank you, Celia, again for the introduction and all your hard work getting today's call together. I'd like to start by congratulating our team for their excellent execution on both the clinical and non-clinical work with KZR-616, which is well represented in four presentations at this year's ACR meeting. At the premier gathering for rheumatology professionals, we're excited to be sharing so many updates on KZR-616 and its novel mechanism. These presentations represent the latest chapter in many years of dedicated R&D effort by our team on KZR-616 and its predecessor molecules. The positive learnings from this dataset have allowed us to enter the next exciting stage of clinical development with three Phase 2 trials recruiting and five different autoimmune indications. We believe the KZR-616 has the potential to transform the lives of patients suffering from these severe diseases and our hard working passionate team is committed to achieving that goal.
Before I pass it over to Chris Kirk, Kezar's Co-Founder, President and CSO, I'd like to briefly recap some of the reasons why we think Kezar represents a compelling investment opportunity. As the first company to bring a selected immunoproteasome inhibitor into the clinic, we feel that Kezar has a substantial head start and the opportunity to characterize the broad potential of this target. Expressed across all immune cell types, immunoproteasome is also inhibited by the myeloma drug VELCADE, which has been used off-label extensively with great effect in patients with severe autoimmune diseases.